In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
The in vitro activity of two new quinolones, difloxacin and A-56620, was compared with that of other quinolones against isolates obtained from bacteremic cancer patients. Both agents had a broad antimicrobial spectrum which included both gram-positive and gram-negative organisms. A-56620 had lower MIC values against most organisms tested than difloxacin, and its activity was comparable to that of ciprofloxacin.
Rolston
K V
KV
Division of Medicine, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston.
Ho
D H
DH
LeBlanc
B
B
Bodey
G P
GP
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000150:complications; D011809:Quinones / Q000494:pharmacology; D018805:Sepsis / Q000150:complications
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011809:Quinones; D002939:Ciprofloxacin; C047225:difloxacin; C047224:sarafloxacin